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Abstract
Background: To analyze predictors and develop predictive models of anatomic outcome in neovascular age-related
macular degeneration (AMD) treated with as-needed ranibizumab after 4 years of follow-up.
Methods: A multicenter consecutive case series non-interventional study was performed. Clinical, funduscopic
and OCT characteristics of 194 treatment-naïve patients with AMD treated with as-needed ranibizumab for at
least 2 years and up to 4 years were analyzed at baseline, 3 months and each year until the end of the follow-up.
Baseline demographic and angiographic characteristics were also evaluated. R Statistical Software was used for
statistical analysis. Main outcome measure was final anatomic status.
Results: Factors associated with less probability of preserved macula were diagnosis in 2009, older age, worse vision,
presence of atrophy/fibrosis, pigment epithelium detachment, and geographic atrophy/fibrotic scar/neovascular AMD
in the fellow eye. Factors associated with higher probability of GA were presence of atrophy and greater number of
injections, whereas male sex, worse vision, lesser change in central macular thickness and presence of fibrosis were
associated with less probability of GA as final macular status. Predictive model of preserved macula vs. GA/fibrotic scar
showed sensibility of 77.78% and specificity of 69.09%. Predictive model of GA vs. fibrotic scar showed sensibility of 68.
89% and specificity of 72.22%.
Conclusions: We identified predictors of final macular status, and developed two predictive models. Predictive models
that we propose are based on easily harvested variables, and, if validated, could be a useful tool for individual patient
management and clinical research studies.
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Background
Age-related macular degeneration (AMD) is the major
cause of visual impairment in developed countries in
people over 60 years [1]. Currently, almost every patient
showing active neovascular AMD undergoes treatment
with drugs targeting vascular endothelial growth factor
(VEGF), as these drugs can slow progression of this form
of the disease [2]. Ranibizumab, an anti-VEGF agent, is
widely used for the management of choroidal neovascu-
larization (CNV) secondary to AMD. Anti-VEGF agents
have shown rare complications associated to its use,
nevertheless, recent reports describe vision-threatening
events noted during follow-up of eyes receiving these
treatments [3]. These events include development of geo-
graphic atrophy (GA) [4] and fibrotic scar formation [5].
The area of a CNV lesion often develops retinal pigment
epithelium (RPE) and choriocapillary atrophy. These
atrophic lesions are clinically indistinguishable from de
novo GA [6]. Fibrotic scar formation within the retina
or the subretinal space occurs in the natural course of
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neovascular AMD [7], and has been identified as an im-
portant cause of visual loss after treatment with anti-
VEGF agents [3]. However, factors associated with GA
and fibrotic scar formation after treatment with ranibi-
zumab remain to be elucidated.
Our study aims to investigate predictive factors associ-
ated to long-term anatomic outcome in patients with
AMD after as-needed treatment with ranibizumab, in-
cluding data collected from seven centres in the Spanish
region of Castilla & León. The identification of these
factors may provide helpful information to predict final
macular status of patients with AMD receiving this
regimen of ranibizumab. Additionally, basing on these
variables, we propose predictive models of anatomic
outcome.
Methods
We performed an observational consecutive case series
study in seven centres in Castilla & León, Spain. A system-
atic review of medical charts of patients with AMD treated
with ranibizumab (Lucentis, Genentech, Inc., South San
Francisco, CA), collected in our database was done. The
study was designed to survey longstanding funduscopic
outcome. Descriptive results of the whole sample have
already been published [8].
Protocol was approved by the ethical committee of the
coordinating centre (Research and Ethics Commission of
IOBA Eye Institute, University of Valladolid, Valladolid,
Spain) and of each participant institution. The study was
conducted in compliance with the guidelines in the
Declaration of Helsinki. Written informed consent was
obtained from all participants.
Patients
The study included treatment-naïve neovascular AMD
patients who started treatment between January 1, 2008
and December 31, 2012, following as-needed regimen of
injections, with at least 2-years of follow-up. Only one
eye of each patient was enrolled; when both eyes met in-
clusion criteria, the eye with longer follow-up was en-
rolled, and selection was made randomly if both had the
same follow-up period. Patients suffering any other asso-
ciated sight-threatening pathology (except for cataract),
late baseline AMD, patients who did not complete at
least 24 months of follow-up, those who discontinued
treatment for any reason during follow-up, and those who
showed no response to treatment (no morphologic nor
functional improvement after 3 ranibizumab injections)
were excluded.
Variables
Baseline characteristics recorded are shown in Table 1.
Total time of follow-up was also noted. Snellen distance
best-corrected visual acuity (BCVA), OCT assessment,
presence of macular-associated lesions and number of
visits and injections were recorded at baseline, 3 months
and at 1, 2, 3 and 4 years of follow-up.
Macular associated lesions were assessed by colour
fundus photographs, fluorescein angiography (FA), fundus
autofluorescence and OCT. These lesions were identified
as bleeding >50%, presence of pigment epithelium detach-
ment (PED), RPE tear, retinal angiomatous proliferation
(RAP), polypoidal vasculopathy and presence of a mini-
mum area of fibrosis or atrophy. These two latter lesions
never involved fovea and were not the main component of
Table 1 Baseline characteristics of patients
Preserved vs.
GA/fibrotic scar
GA vs. fibrotic scar
Characteristics n = 194 n = 153












Delay of treatment (n)
< 30 days 128 99
(30–90] days 50 43
> 90 days 16 11
Angiographic type of lesion (n)
Classic 43 36
Predominantly classic 13 11
Minimally classic 14 13
Occult 62 45
Others 3 2
Status of the fellow eye (n)
Initial/intermediate AMD 75 54
Neovascular 13 9
Atrophic 38 36
Disciform scar 37 30
Others 21 15




GA geographic atrophy, AMD age-related macular degeneration
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lesion. Snellen distance BCVA was transformed into the
logarithm of the minimum angle of resolution (logMAR),
using a validated procedure [9]. OCT morphology data
(presence or absence of subretinal fluid and/or thickening
>100 μm compared to the previous visit, (both or none)
was also gathered. Central macular thickness change was
evaluated following a procedure previously described [8].
Final funduscopic status of the studied eye was classi-
fied as active, inactive with predominantly fibrotic disci-
form scar, inactive with predominantly atrophic scar and
inactive well-preserved macula, and the rest were excluded
of the study. To assess predictive factors and models of
anatomic outcome, only eyes with final fibrotic scar, atro-
phy or well-preserved macula at the end of the study were
analysed. To classify funduscopic results of contralateral
eye, International ARM classification was used [10].
Statistical analysis
Quantitative characteristics were expressed as mean ±
standard deviation (SD), and qualitative variables were
described in percentages. Statistical analysis was per-
formed using R Statistical Software (R Core Team;
Vienna, Austria) [11]. To avoid influence of missing
data we used the Copy Mean method [12], implemented
at the Package Longitudinal Data of R (Longitudinal Data.
R package version 2.2).
Depending on the main variable assessed, the statis-
tical analysis was divided in two sections. First, probabil-
ity of macular preservation was compared to probability
of either GA or fibrotic scar. For the second part of the
assessment, eyes showing well-preserved macula as final
anatomic status were excluded, and probability of GA at
the end of the follow-up was compared to probability of
fibrotic scar.
A binary logistic regression model was fitted to identify
potential predictors of functional outcome between col-
lected variables. Estimated odds ratio (OR) was used to
quantify the importance of each potential predictor. Vari-
ables with a univariate p value lower than 0.1 were identified
as relevant predictors. Then, we performed a multivariate lo-
gistic regression model based on the best set of relevant pre-
dictors according to Akaike Information Criteria [13]. The
bestglm package [14] was used to enumerate and evaluate
all possible models. Inter-correlation between the fi-
nally selected predictors was evaluated using the Vari-
ance Inflation Factor implemented in the car package
[15]. A Variance Inflation Factor value higher than 5 in-
dicated presence of multicollinearity.
In order to assess the performance of prediction model,
a leave-one-out cross-validation process was used for in-
ternal validation. Three aspects were evaluated: precision,
calibration and discrimination ability.
The Brier Score was used as global measure of the
precision [16]. This score is based upon individual
differences between predicted risks in terms of likeli-
hood and observed final outcomes. The Brier score
ranges, from 0 for a perfect degree of agreement to 1 for
the worst possible degree of agreement.
To evaluate the calibration of the model, two measures
were used: the calibration-in-the large, that, in a perfectly
calibrated model will be 0, and the Calibration Slope
that in such model will be 1. We also used the Hosmer-
Lemeshow test, which is significant for badly calibrated
models [17].
Receiver Operating Characteristic (ROC) curve analysis
was used to assess the discrimination ability of the fitted
models. They were evaluated and compared according
to the area under the ROC curve (AUC). In addition,
the sensitivity and specificity for the ROC curve was
obtained by setting an optimal threshold using the
pROC package [18].
Results
Notes from 1236 patients treated with anti-VEGF drugs at
seven hospitals were evaluated, and 314 eyes were identi-
fied as eligible [8]. Nevertheless, for this part of the study
61 eyes that had discontinued treatment were excluded,
and so were those with active or unclassifiable macular
anatomic status, thus, 194 eyes (194 patients, 112 women
and 82 men) were analysed. Baseline characteristics of the
sample appear in Table 1.
First, to study predictive factors and models of prob-
ability of well-preserved macula, data from 194 eyes pre-
senting late AMD were used, from which 153 showed
either GA/fibrotic scar and 41 showed well-preserved
macula. Afterwards, a second study was performed with
a sample of 153 eyes, those 153 with GA/scar, from
which 72 showed GA and 81 fibrotic scar.
Preserved vs. GA/fibrotic scar
To determine factors associated to anatomic preservation
versus developing GA or fibrotic scar, a subset of 194 eyes
from 194 patients (116 women, 78 men) were included.
Mean age was 78.01 years (range 55–93; SD 7.55). Mean
follow-up was 98.03 months (range 24.3–161.5; SD 28.08;
median 98.25). After 4 years of follow-up, 41 eyes pre-
sented preserved macular anatomy (21.13%) and 153 pre-
sented GA or fibrotic scar (78.87%).
Results of univariate analysis appear in Table 2. Statis-
tically significant higher probability of preserved macular
anatomy was found among patients with transparent
lens. Contrarily, negative predictors of preserved macu-
lar anatomy, were diagnosis in 2009, older age, worse
BCVA in all visits, PED at 1 and 2 years, small area of
atrophy (not involving the fovea nor being the main
component of lesion) at 1 and 4 years of follow-up, small
area of fibrosis (not involving the fovea nor being the
main component of lesion) at 2, 3 and 4 years, atrophic
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Table 2 Univariate analysis for preserved vs. geographic atrophy/fibrotic scar
Baseline 3 months
n (%) OR CI 95% p-value n (%) OR IC 95% p-value
Age 194 0.9473 0.9058 0.9907 0.018 - - - - -
Sex
Female 116 (59.79) 1 - - - - - - - -
Male 78 (40.21) 0.7211 0.3506 0.1.4829 0.374 - - - - -
Year of diagnosis
2007 4 (2.06) 0.619 0.0588 6.5209 0.6897 - - - - -
2008 49 (25.26) 0.4762 0.1839 1.2328 0.1263 - - - - -
2009 101 (52.06) 0.3496 0.1508 0.8106 0.0143 - - - - -
2010 40 (20.62) 1 - - - - - - - -
Delay of treatment
< 30 days 128 (65.98) 1 - - - - - - - -
(30–90] days 50 (25.77) 0.5557 0.226 1.3664 0.2006 - - - - -
> 90 days 16 (8.25) 1.5517 0.4986 4.8289 0.4481 - - - - -
Angiographic type of lesion
Classic 43 (31.85) 0.5147 0.1925 1.3759 0.1855 - - - - -
Predominantly classic 13 (9.63) 0.4813 0.0965 2.3997 0.3723 - - - - -
Minimally classic 14 (10.37) 0.2036 0.0247 1.678 0.1391 - - - - -
Occult 62 (45.93) 1 - - - - - - - -
Others 3 (2.22) 1.3235 0.1126 15.5608 0.8236 - - - - -
Status of the fellow eye
Initial/intermediate AMD 75 (40.76) 1 - - - - - - - -
Neovascular 13 (7.07) 1.1429 0.3174 4.115 0.8381 - - - - -
Atrophic 38 (20.65) 0.1429 0.0315 0.6469 0.0116 - - - - -
Disciform scar 37 (20.11) 0.6 0.2286 1.5746 0.2994 - - - - -
Others 21 (11.41) 1.0286 0.3519 3.0064 0.9589 - - - - -
Status of the lens
Cataract 108 (64.29) 1 - - - - - - - -
Pseudophakia 53 (31.55) 1.43 0.6477 3.1572 0.3761 - - - - -
Transparent 7 (4.17) 5.8667 1.216 28.3039 0.0276 - - - - -
BCVA 194 0.1296 0.0477 0.3517 0.0001 194 0.0668 0.0194 0.2301 <0.0001
CMT change - - - - - 191 0.8438 0.2975 2.3933 0.7496
OCT assessment
SRF 49 (28) 0.4263 0.0917 1.9823 0.2769 60 (31.91) 1.3636 0.6457 2.8796 0.4161
Thickening 21 (12) 4.05 0.5372 30.5344 0.1748 7 (3.72) - - - 0.9867
Both 101 (57.71) 1 - - - 9 (4.79) 0.5114 0.0607 4.3051 0.5372
None 4 (2.29) 1.7868 0.819 3.8982 0.1448 112 (59.57) 1 - - -
Macular associated lesions
Bleeding >50% 20 (14.6) 0.402 0.1046 1.5454 0.1847 5 (4.24) 0.6964 0.0716 6.7734 0.7553
PED 37 (27.01) 0.3559 0.1193 1.0621 0.064 23 (19.49) 0.2653 0.055 1.28 0.0984
RPE tear 2 (1.46) - - - 0.9969 3 (2.54) - - - 0.9976
Initial minimal atrophy 5 (3.65) - - - 0.9951 8 (6.78) - - - 0.9961
Initial minimal fibrosis 10 (7.3) - - - 0.9931 23 (19.49) - - - 0.9934
RAP 2 (1.46) 2.2778 0.1349 38.4694 0.5681 2 (1.69) 2.7857 0.163 47.597 0.4793
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Table 2 Univariate analysis for preserved vs. geographic atrophy/fibrotic scar (Continued)
PV 2 (1.46) - - - 0.9969 1 (0.85) - - - 0.9985
Others 59 (43.07) - - - - 53 (44.92) - - - -
Total time of treatment - - - - - - - - - -
Number of injections - - - - - 194 1.9616 0.9564 4.0233 0.066
Number of visits - - - - - 170 1.4041 0.8748 2.2536 0.1598
1 year 2 years
n (%) OR CI 95% p-value n (%) OR CI 95% p-value
Age - - - - - - - - - -
Sex
Female - - - - - - - - - -
Male - - - - - - - - - -
Year of diagnosis
2007 - - - - - - - - - -
2008 - - - - - - - - - -
2009 - - - - - - - - - -
2010 - - - - - - - - - -
Delay of treatment
< 30 days - - - - - - - - - -
(30–90] days - - - - - - - - - -
> 90 days - - - - - - - - - -
Angiographic type of lesion
Classic - - - - - - - - - -
Predominantly classic - - - - - - - - - -
Minimally classic - - - - - - - - - -
Occult - - - - - - - - - -
Others - - - - - - - - - -
Status of the fellow eye
Initial/intermediate AMD - - - - - - - - - -
Neovascular - - - - - - - - - -
Atrophic - - - - - - - - - -
Disciform - - - - - - - - - -
Others - - - - - - - - - -
Status of the fellow eye
Cataract - - - - - - - - - -
Pseudophakia - - - - - - - - - -
Transparent - - - - - - - - - -
BCVA 194 0.0227 0.0058 0.0891 <0.0001 194 0.0694 0.026 0.1851 <0.0001
CMT change 192 0.5216 0.1953 1.3932 0.1941 192 1.3015 0.5533 3.0618 0.546
OCT assessment
SRF 52 (27.96) 0.6667 0.2882 1.542 0.2769 33 (18.33) 1.5 0.6232 3.6105 0.3656
Thickening 11 (5.91) 0.7078 0.1441 3.478 0.1748 6 (3.33) 2 0.3472 11.52 0.4378
Both 10 (5.38) 0.3539 0.0429 2.9208 - 11 (6.11) 0.8889 0.181 4.3646 0.8847
None 113 (60.75) 1 - - 0.1448 130 (72.22) 1 - - -
Macular associated lesions
Bleeding >50% 1 (0.76) - - . 0.9986 1 (0.75) - - - 0.9986
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Table 2 Univariate analysis for preserved vs. geographic atrophy/fibrotic scar (Continued)
PED 17 (12.88) 0.0882 0.0107 0.7305 0.0244 18 (13.43) 0.2267 0.0547 0.9385 0.0406
RPE tear 4 (3.03) 0.4706 0.045 4.9191 0.529 2 (1.49) - - - 0.998
Initial minimal atrophy 22 (16.67) 0.1412 0.0291 0.6859 0.0152 26 (19.4) - - - 0.9926
Initial minimal fibrosis 47 (33.61) - - - 0.9902 54 (40.3) 0.0436 0.009 0.2103 0.0001
RAP 0 (0) - - - - 0 (0) - - - -
PV 0 (0) - - - - 1 (0.75) - - - 0.9986
Others 41 (31.06) 1 - - - 32 (23.88) 1 - - -
Total time of treatment - - - - - - - - - -
Number of injections 194 1.2133 0.9583 1.5362 - 189 1.1721 0.9163 1.4992 0.2062
Number of visits 184 1.1135 0.9391 1.3202 - 187 1.0613 0.9327 1.2076 0.3666
3 years 4 years
n (%) OR CI 95% p-value n (%) OR CI 95% p-value
Age - - - - - - - - - -
Sex
Female - - - - - - - - - -
Male - - - - - - - - - -
Year of diagnosis
2007 - - - - - - - - - -
2008 - - - - - - - - - -
2009 - - - - - - - - - -
2010 - - - - - - - - - -
Delay of treatment
< 30 days - - - - - - - - - -
(30–90] days - - - - - - - - - -
> 90 days - - - - - - - - - -
Angiographic type of lesion
Classic - - - - - - - - - -
Predominantly classic - - - - - - - - - -
Minimally classic - - - - - - - - - -
Occult - - - - - - - - - -
Others - - - - - - - - - -
Status of the fellow eye
Initial/intermediate AMD - - - - - 50 (27.17) 1 - - -
Neovascular - - - - - 21 (11.41) 0.075 0.0093 0.6042 0.015
Atrophic - - - - - 50 (27.17) 0.1304 0.0406 0.4194 0.0006
Disciform scar - - - - - 44 (23.91) 0.3857 0.1529 0.9733 0.0437
Others - - - - - 19 (10.33) 0.6923 0.2257 2.1232 0.5201
Status of the lens
Cataract - - - - - - - - - -
Pseudophakia - - - - - - - - - -
Transparent - - - - - - - - - -
BCVA 194 0.0523 0.0182 0.1501 <0.0001 194 0.0595 0.0219 0.1616 <0.0001
CMT change 192 1.2116 0.5475 2.6811 0.6358 192 1.3213 0.6428 2.7159 0.4485
OCT assessment
SRF 19 (14.62) 0.9576 0.2885 3.1789 0.9435 5 (7.68) - - - 0.9926
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AMD in the fellow eye at baseline and at the end of the
follow-up, neovascular AMD in the fellow eye at the end
of the follow-up, and fibrotic scar in the fellow eye at
the end of the follow-up.
Then, multivariate analysis (Fig. 1) to find the best
predictive model was performed using those previous
variables with p < 0.1 and measurements recorded after
the first year of follow-up were excluded, as they would
have low predictive value. Thus, diagnosis in 2009, age,
baseline BCVA, PED at baseline, number of injections
at 3 months and presence of atrophy within the fellow
eye at baseline were considered.
The best-fitted model found (Fig. 1) included 3 vari-
ables: age, baseline BCVA and number of injections at
3 months.
Geographic atrophy vs. fibrotic scar
A subset of 153 eyes from 153 patients (89 women, 62
men) was analysed for this purpose. Mean age was
78.68 years (range 55–93; SD 7.19). Mean follow-up was
97.24 months (range 24.3–161.5; SD 27.3; median 98).
After 4 years of follow-up, 72 eyes presented GA (47.06%)
whereas 81 eyes presented fibrotic scar (52.94%). Results of
univariate analysis are shown in Table 3.
Regarding univariate analysis results, statistically signifi-
cant factors associated with higher probability of GA were:
small area of atrophy (not involving the fovea nor being
the main component of lesion) at 2 and 3 years of follow-
up, and the greater number of injections at 3 months, 3
and 4 years. On the other hand, negative predictors of
GA, were male sex, lower vision at 2, 3 and 4 years of
follow-up, the lower change in central macular thickness
at 2, 3 and 4 years, and presence of a small area of fibrosis
(not involving the fovea nor being the main component of
lesion) at 3 months, 1 and 2 years of follow-up.
Multivariate analysis (Fig. 2) to find the best predictive
model was performed using those previous variables
with p < 0.1. Measurements after the first year of follow-
up were excluded, as they would have low predictive value.
As a result, sex, diagnosis in 2009, presence of a small area
of fibrosis at 3 months, and number of injections at
3 months were chosen, and the best-fitted model (Fig. 2)
included the 4 of them.
Discussion
In this study, we identify potential predictors and intro-
duce new predictive models of final anatomic outcome
in neovascular AMD treated with as-needed ranibizu-
mab. Previous models aim to identify patients at early or
intermediate stages at high risk of advanced AMD, and
many of them include a combination of demographic,
clinical, genetic and environmental variables [19–21].
We propose two predictive models of anatomic outcome
based on selected demographic and clinical features eas-
ily harvested in the daily clinical routine. Descriptive re-
sults of this sample have been previously published [8].
We assessed presence of GA by analysing colour fun-
dus photographs, fundus autofluorescence and OCT. In
our sample, 37.11% of patients with inactive macular sta-
tus showed GA at the end of the follow-up. Comparison
of Age-Related Macular Degeneration Treatments Trials
(CATT) study reported new GA lesions in 12.9–25.8%
Table 2 Univariate analysis for preserved vs. geographic atrophy/fibrotic scar (Continued)
Thickening 5 (3.85) 0.8977 0.0954 8.4467 0.9248 1 (1.52) - - - 0.9962
Both 5 (3.85) 5.3864 0.8465 34.2744 0.0745 3 (4.55) 1.5357 0.1292 18.248 0.7341
None 101 (77.69) 1 - - - 57 (86.36) 1 - - -
Macular associated lesions
Bleeding >50% 0 (0) - - - - 0 (0) - - - -
PED 9 (8.65) 0.1136 0.012 1.0764 0.058 1 (1.82) - - - 0.9963
RPE tear 3 (2.28) - - - 0.9975 1 (1.82) - - - 0.9963
Initial minimal atrophy 26 (25) - - - 0.9926 13 (23.64) 0.0417 0.0035 0.4908 0.0115
Initial minimal fibrosis 45 (43.27) 0.0423 0.0081 0.2216 0.0002 31 (56.36) 0.0167 0.0015 0.1887 0.0009
RAP 0 (0) - - - - 0 (0) - - - -
PV 0 (0) - - - - 0 (0) - - - -
Others 21 (20.19) 1 - - - 9 (16.36) 1 - - -
Total time of treatment - - - - - 194 1.0131 0.982 1.0453 0.4134
Number of injections 147 1.0238 0.8646 1.2122 0.7852 71 1.0032 0.8306 1.2116 0.9738
Number of visits 147 1.1359 0.9571 1.3482 0.1448 76 0.9568 0.7498 1.2211 0.7229
A total of 194 patients were included in the final univariate analysis for presence of preserved macula vs. geographic atrophy/fibrotic scar. This table shows all the
variables evaluated in each visit during the 4 years of follow-up. OR: odds ratio, CI: confidence interval, AMD: age-related macular degeneration, BCVA: best corrected
visual acuity, CMT: central macular thickness, SRF: subretinal fluid, PED: pigment epithelium detachment, RPE: retinal pigment epithelium, RAP: retinal angiomatous
proliferation, PV: polypoidal vasculopathy. Statistically significant results appear in italic
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of patients with no GA at enrolment after 2 years of
follow-up, in patients randomly assigned to injections of
ranibizumab or bevacizumab and to a 2-year dosing
regimen of monthly or PRN or to monthly for 1 year
and PRN the following year [6]. Independent baseline risk
factors found in CATT for GA development included
poor BCVA, RAP, foveal intraretinal fluid, monthly dosing,
and treatment with ranibizumab [6]. Thus, anti-VEGF
therapy was suggested to play a role in GA development.
In the present study, we included patients who showed
a small area of atrophy at baseline, not involving the
fovea nor being the main component of lesion, but we
did not find baseline atrophy associated with further de-
velopment of GA. However, presence of atrophy at 2
and 3 years of follow-up was associated with higher
probability of GA as final macular status. Also, the greater
number of injections was associated with GA, and this fact
reinforces the association of GA with anti-VEGF therapy
previously proposed. Interestingly, GA development has
only been observed during the treatment of AMD, in
which GA is part of the natural history of the disease, and
has not been observed during the course of other diseases
managed by multiple injections of anti-VEGF drugs.
Furthermore, the study of growth of GA performed by
CATT showed that eyes with GA farther from the
fovea, which we included in the present study, had
higher growth rates by 0.14 mm/year for every millimetre
farther from the fovea [22]. This could explain the fact
that, in our sample, we found a significant association be-
tween macular atrophy and final GA, and may represent
the evolution of the disease.
Another recent study, in which RPE atrophy was
monitored using polarization-sensitive OCT, revealed
an increase in atrophic RPE features and GA dimension
on 61% of patients at 2 years of follow-up following a
similar regimen of injections with ranibizumab [23]. Add-
itionally, Tanaka et al. in a retrospective study, observed
GA developing outside CNV margin only in those eyes
that showed GA outside the lesion at baseline, suggesting
that atrophic scars that mimic GA could emerge within
the area originally occupied with a CNV [3]. In this study
we included atrophic scars in the term GA, and they are
referred to as GA throughout this report.
SEVEN-UP study enrolled patients from the ANCHOR
and MARINA trials, that had received 2 years of monthly
ranibizumab followed by an additional 2 years of as-
needed ranibizumab treatment in the HORIZON proto-
col, and were recalled for evaluation at 7 to 8 years after
their enrolment. In this study they detected macular atro-
phy by fundus autofluorescence analysis in 98% of study
eyes, and 90% showed decreased autofluorescence involv-
ing the fovea at the end of the follow-up [24]. Predictors
found to be associated with final atrophy at SEVEN-UP
were baseline area of atrophy and baseline area of leaking
CNV [25]. As evolution to atrophy can limit the result of
treatment with anti-angiogenic drugs, further studies aim-
ing to avoid this evolution will be needed. Our predictive
models could help to selecting patients to be enrolled in
such studies.
CATT study analysed the risk of scar development in a
recent report [5]. Scars were classified as fibrotic and
nonfibrotic attending to their characteristics observed at
colour fundus photographs and FA. Fibrotic scars are
relatively easy to recognize at ophthalmoscopy. On the
contrary, as nonfibrotic scars are funduscopically identi-
cal to de novo GA, they were distinguished by FA [5].
As mentioned before, we included atrophic scars in the
term GA, because, as this is an observational study and
Fig. 1 Multivariate analysis and predictive model Receiver Operating Characteristic (ROC) curve of preserved macula vs. geographic atrophy/fibrotic
scar. The upper chart shows results of multivariate analysis. The figure below shows ROC curve of the predictive model. The area under the curve
reveals that this model has a good reliability in the prediction of final macular anatomic status. The greyish area indicates where the model loses its
reliability. Besides, on the right internal validation data is shown. CI: confidence interval, AUC: area under the curve, CL: calibration in the large,
CS: calibration slope
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Table 3 Univariate analysis for geographic atrophy vs. fibrotic scar
Baseline 3 months
n (%) OR CI 95% p-value n (%) OR CI 95% p-value
Age 153 1.0119 0.9678 1.058 0.6024 - - - - -
Sex
Female 89 (58.17) 1 - - - - - - - -
Male 64 (41.83) 0.4579 0.2368 0.8857 0.0203 - - - - -
Year of diagnosis
2007 3 (1.96) 0.9444 0.075 11.8891 0.9647 - - - - -
2008 39 (25.49) 1.314 0.4693 3.6789 0.6031 - - - - -
2009 85 (55.56) 2.2279 0.8935 5.5553 0.0857 - - - - -
2010 26 (16.99) 1 - - - - - - - -
Delay of treatment
< 30 days 99 (64.71) 1 - - - - - - - -
(30–90] days 43 (28.1) 0.8411 0.4097 1.7271 0.6374 - - - - -
> 90 days 11 (7.19) 0.8854 0.2535 3.0921 0.8487 - - - - -
Angiographic type of lesion
Classic 36 (33.64) 1.1957 0.4961 2.8816 0.6905 - - - - -
Predominantly classic 11 (10.28) 0.3587 0.0841 1.5291 0.1658 - - - - -
Minimally classic 13 (12.15) 0.5978 0.1694 2.1097 0.4239 - - - - -
Occult 45 (42.06) 1 - - - - - - - -
Others 2 (1.87) - - - 0.9879 - - - - -
Status of the fellow eye
Initial/intermediate AMD 54 (37.5) 1 - - - - - - - -
Neovascular 9 (6.25) 4.375 0.8314 23.0235 0.1015 - - - - -
Atrophic 36 (25) 0.8929 0.3806 2.0947 0.7945 - - - - -
Disciform scar 30 (20.83) 1.25 0.511 3.0579 0.6249 - - - - -
Others 15 (10.42) 0.625 0.1882 2.0755 0.4428 - - - - -
Status of the lens
Cataract 88 (67.18) 1 - - - - - - - -
Pseudophakia 40 (30.53) 1.1679 0.5516 2.4728 0.6851 - - - - -
Transparent 3 (2.29) 1.9111 0.1671 21.8512 0.6024 - - - - -
BCVA 153 0.8892 0.4752 1.6636 0.7132 153 1.0638 0.5598 2.0217 0.8502
CMT change - - - - - 150 1.4185 0.5473 3.677 0.4718
OCT assessment
SRF 34 (25) 1.25 0.5603 2.7889 0.5858 45 (30) 1.4286 0.6966 2.9297 0.3304
Thickening 19 (13.97) 0.9091 0.3309 2.4976 0.8534 7 (4.67) 1.6667 0.3525 7.8809 0.5193
Both 81 (59.56) 1 - - - 8 (5.33) 0.1786 0.0211 1.5119 0.1139
None 2 (1.47) 1.25 0.0755 20.6845 0.8762 90 (60) 1 - - -
Macular associated lesions
Bleeding >50% 17 (15.45) 0.8466 0.2729 2.6266 0.7731 4 (4.04) 0.2857 0.0273 2.9932 0.2959
PED 32 (29.09) 1.2245 0.4837 3.1 0.6691 21 (21.21) 0.6429 0.2207 1.8728 0.418
RPE tear 2 (1.82) - - - 0.9922 3 (3.03) 1.7143 0.1433 20.504 0.6703
Initial minimal atrophy 5 (4.55) 1.4286 0.2156 9.4665 0.7119 8 (8.08) 2.5714 0.4606 14.355 0.2817
Initial minimal fibrosis 10 (9.09) 0.2381 0.045 1.2599 0.0914 23 (23.23) 0.3025 0.0983 0.9306 0.037
RAP 1 (0.91) - - - 0.9945 1 (1.01) - - - 0.9914
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Table 3 Univariate analysis for geographic atrophy vs. fibrotic scar (Continued)
PV 2 (1.82) - - - 0.9922 0 (0) - - - -
Others 41 (37.27) 1 - - - 39 (39.39) 1 - - -
Total time of treatment - - - - - - - - - -
Number of injections - - - - - 153 2.5099 1.318 4.7796 0.0051
Number of visits - - - - - 133 0.9856 0.6336 1.5332 0.9486
1 year 2 years
n (%) OR CI 95% p-value n (%) OR CI 95% p-value
Age - - - - - - - - - -
Sex
Female - - - - - - - - - -
Male - - - - - - - - - -
Year of diagnosis
2007 - - - - - - - - - -
2008 - - - - - - - - - -
2009 - - - - - - - - - -
2010 - - - - - - - - - -
Delay of treatment
< 30 days - - - - - - - - - -
(30–90] days - - - - - - - - - -
> 90 days - - - - - - - - - -
Angiographic type of lesion
Classic - - - - - - - - - -
Predominantly classic - - - - - - - - - -
Minimally classic - - - - - - - - - -
Occult - - - - - - - - - -
Others - - - - - - - - - -
Status of the fellow eye
Initial/intermediate AMD - - - - - - - - - -
Neovascular - - - - - - - - - -
Atrophic - - - - - - - - - -
Disciform scar - - - - - - - - - -
Others - - - - - - - - - -
Status of the lens
Cataract - - - - - - - - - -
Pseudophakia - - - - - - - - - -
Transparent - - - - - - - - - -
BCVA 153 0.6119 0.3314 1.1298 0.1164 153 0.313 0.1742 0.5623 0.0001
CMT change 151 1.234 0.5158 2.9522 0.6367 151 0.5479 0.2503 1.1994 0.1323
OCT assessment
SRF 43 (29.25) 0.9004 0.4568 1.9927 0.9004 24 (17.02) 1.0262 0.421 2.5014 0.9547
Thickening 9 (6.12) 0.4934 0.1414 2.5674 0.4934 4 (2.84) - - - 0.9891
Both 9 (6.12) 0.2342 0.5657 10.2697 0.2342 9 (6.38) 1.516 0.3851 5.9677 0.5518
None 86 (58.5) 1 - - - 104 (73.76) 1 - - -
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Table 3 Univariate analysis for geographic atrophy vs. fibrotic scar (Continued)
Macular associated lesions
Bleeding >50% 1 (0.9) - - - 0.9944 1 (0.88) - - - 0.9944
PED 16 (14.41) 0.7143 0.2001 2.5495 0.6042 15 (13.16) 0.4667 0.1135 1.9195 0.2909
RPE tear 3 (2.7) - - - 0.9907 2 (1.75) - - - 0.9924
Initial minimal atrophy 20 (18.02) 2.1429 0.5856 7.8414 0.2495 26 (22.81) 5.3667 1.1472 25.105 0.0328
Initial minimal fibrosis 47 (42.34) 0.1931 0.0662 0.5632 0.0026 52 (45.61) 0.1273 0.0374 0.4332 0.001
RAP 0 (0) - - - - 0 (0) - - - -
PV 0 (0) - - - - 1 (0.88) - - - 0.9946
Others 24 (21.62) 1 - - - 17 (14.91) 1 - - -
Total time of treatment - - - - - - - - - -
Number of injections 153 1.1762 0.9157 1.5107 0.2038 150 1.0851 0.8399 1.4021 0.5319
Number of visits 146 1.1098 0.9481 1.2991 0.1949 146 0.9166 0.7719 1.0885 0.3207
3 years 4 years
n (%) OR CI 95% p-value n (%) OR CI 95% p-value
Age - - - - - - - - - -
Sex
Female - - - - - - - - - -
Male - - - - - - - - - -
Year of diagnosis
2007 - - - - - - - - - -
2008 - - - - - - - - - -
2009 - - - - - - - - - -
2010 - - - - - - - - - -
Delay of treatment
< 30 days - - - - - - - - - -
(30–90] days - - - - - - - - - -
> 90 days - - - - - - - - - -
Angiographic type of lesion
Classic - - - - - - - - - -
Predominantly classic - - - - - - - - - -
Minimally classic - - - - - - - - - -
Occult - - - - - - - - - -
Others - - - - - - - - - -
Status of the fellow eye
Initial/intermediate AMD - - - - - 30 (20.83) 1 - - -
Neovascular - - - - - 20 (13.89) 0.6667 0.212 2.0963 0.4879
Atrophic - - - - - 46 (31.94) 0.84 0.3343 2.1105 0.7107
Disciform scar - - - - - 35 (24.31) 1.0588 0.3992 2.8085 0.9086
Others - - - - - 13 (9.03) 0.4444 0.112 1.7634 0.2488
Status of the lens
Cataract - - - - - - - - - -
Pseudophakia - - - - - - - - - -
Transparent - - - - - - - - - -
BCVA 153 0.2781 0.1539 0.5026 <0.0001 153 0.3332 0.1982 0.56 <0.0001
CMT change 151 0.4459 0.2122 0.937 0.003 151 0.4485 0.226 0.8901 0.0219
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we didn’t perform FA at the end of the follow-up. CATT
study reported 45.3% of scar development after 2 years
of follow-up, and predictors for scar formation (either
fibrotic or nonfibrotic) included classic CNV, blocked
fluorescence on FA, increased retinal thickness, foveal
subretinal fluid and dome-shaped subretinal hyperre-
flective material [5].
SEVEN-UP study reported 61.4% of the study eyes
showing macular subretinal fibrosis and 38.6% of the
eyes presenting fibrosis involving the foveal centre [24].
Given the absence of fibrotic scar in almost 40% of study
eyes, it was hypothesized that anti-VEGF therapy may
alter the natural course of neovascular AMD by prolong-
ing the active phase of the disease by preserving outer ret-
ina and RPE [24]. In our sample, 41.75% of the eyes with
inactive AMD at the end of the follow-up showed fibrotic
scar, although follow-up period was shorter. Based on our
clinical experience, fibrosis is a complication that appears
Table 3 Univariate analysis for geographic atrophy vs. fibrotic scar (Continued)
OCT assessment
SRF 15 (15) 1.1722 0.3878 3.543 0.7784 5 (10) 2.8 0.4205 18.644 0.2871
Thickening 4 (4) 0.3419 0.0341 3.4296 0.3616 0 (0) - - - -
Both 2 (2) - - - 0.988 2 (4) - - - -
None 79 (79) 1 - - - 43 (86) 1 - - -
Macular associated lesions
Bleeding >50% 0 (0) - - - - 0 (0) - - - -
PED 8 (8.89) 0.5 0.065 3.8453 0.5054 1 (2.13) - - - 0.9947
RPE tear 3 (3.33) - - - 0.9902 1 (2.13) - - - 0.9943
Initial minimal atrophy 26 (28.89) 6.3 1.2752 31.1244 0.0239 12 (25.53) 6 0.3901 92.277 0.1988
Initial minimal fibrosis 43 (47.78) 0.3971 0.0919 1.7149 0.2159 30 (63.83) 0.4 0.0301 5.3073 0.4873
RAP 0 (0) - - - - 0 (0) - - - -
PV 0 (0) - - - - 0 (0) - - - -
Others 10 (11.11) 1 - - - 3 (6.38) 1 - - -
Total time of treatment - - - - - 153 0.9844 0.9557 1.014 0.2991
Number of injections 114 1.4048 1.081 1.8254 0.011 55 1.3943 1.01 1.9249 0.0434
Number of visits 114 0.9166 0.7719 1.0885 0.3207 58 1.1477 0.9012 1.4617 0.2642
A total of 153 patients were included in the final univariate analysis for presence of geographic atrophy vs. fibrotic scar. This table shows all the variables
evaluated in each visit during the 4 years of follow-up. OR: odds ratio, CI: confidence interval, AMD: age-related macular degeneration, BCVA: best corrected visual
acuity, CMT: central macular thickness, SRF: subretinal fluid, PED: pigment epithelium detachment, RPE: retinal pigment epithelium, RAP: retinal angiomatous
proliferation, PV: polypoidal vasculopathy. Statistically significant results appear in italic
Fig. 2 Multivariate analysis and predictive model Receiver Operating Characteristic (ROC) curve of geographic atrophy vs. fibrotic scar. The upper
chart shows results of multivariate analysis. The figure below shows ROC curve of the predictive model. The area under the curve reveals that this
model has moderate reliability in the prediction of final macular anatomic status. The greyish area indicates where the model loses its reliability.
Besides, on the right internal validation data is shown. CI: confidence interval, AUC: area under the curve, CL: calibration in the large, CS: calibration slope
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earlier than atrophy, which explains that in our study we
found similar percentages of fibrosis compared with
SEVEN-UP, with longer follow-up.
We found transparent lens associated to preserved
macular anatomy at the end of the follow-up, however,
we rejected this as a valid predictor due to the fact that
only 3 out of 131 studied eyes for this variable showed
this condition.
Both predictive models showed AUC values significantly
different from 0.5 and, consequently, are considered ap-
propriate. Predictive model for GA vs. fibrotic scar showed
an AUC = 0.635 and included diagnosis in 2009, presence
of fibrosis at 3 months and number of injections at
3 months. Curiously, in the year 2009, we observed in-
appropriately low mean number of visits (5.37) and in-
jections (0.86), so we decided investigate the year of
diagnosis as a variable. As a result, diagnosis in 2009
was associated with less probability of preserved mac-
ula, although number of visits and number of injections
were not identified as predictors of preserved macula at
any time point. In this year, pro re nata treatment basis
were being established [26, 27], and this fact may justify
the low number of visits and injections, and may have
interfered with our results. Furthermore, patients enrolled
in this study showed better outcomes from the year
2010 on.
The predictive model of preserved macula vs. GA/fibrotic
scar showed a greater AUC (0.76). Therefore, it was consid-
ered a more suitable model than the other, and included
age, baseline BCVA, and number of injections at 3 months.
This highlights these factors as important predictors of final
macular status, and, according to our results, young pa-
tients, those with good baseline vision and those who re-
ceive a correct loading dose would have greater probability
of well-preserved macula as final anatomic status. Besides,
these anatomic predictors have been previously identified
as visual predictors [28].
In the current study we find some limitations. First, as
data were collected from medical charts, they might not
contain all the information needed. Also, daily clinical
routine does not allow a strict regimen of visits and
treatment as performed in clinical trials, so that, variabil-
ity could exist at this point. For this reason, we identified
number of injections at 3 months (90 days) as a pre-
dictor, but this number should be the same (3) for all pa-
tients according to as-needed treatment protocol. All
patients enrolled in our study had received loading dose
in a reasonable period of time, however, as this study
was performed on a daily clinical practice basis, the
interval between injections was not as strict as in clin-
ical trials (30 days), and this resulted in a mean number
of injections at 3 months of 2.54 instead of 3. Besides,
reproducibility of this study may be limited due to the
characteristics of the design. Another important limitation
was the high number of dropouts, mainly due to the fact
that we excluded those patients who had not completed
the follow-up period. Moreover, we excluded patients who
did not respond to treatment, and this could have inter-
fered with final outcomes. We did not exclude patients
presenting a small area of atrophy or fibrosis at baseline,
and development of GA or fibrotic scar could represent
the progression of the disease. Finally, our predictive
models are based on easily harvested clinical and demo-
graphic risk factors, and could be attractive and practical
to apply in the clinical routine. However, the addition of
other variables, such as genetic factors, which are more
difficult to obtain, could increase the sensitivity and speci-
ficity of the models.
Conclusions
We have identified predictors of final macular status, and
additionally, based on these predictors we propose two
predictive models. Predictive model of preserved macula
should be validated in a prospective study with a different
cohort of patients to be considered as a useful tool for in-
dividual patient management and clinical research studies.
Acknowledgements
Authors would like to thank Dr. M Castrejon from the IOBA Eye Institute,
University of Valladolid, Valladolid, Spain; Dr. MI Lopez-Galvez from the Clinic
University Hospital of Valladolid, Valladolid, Spain; Dr. L. Monje-Fernandez from
the University Health Complex of Leon, Leon, Spain; Dr. M Fernandez-Munoz
from the Health Complex of Palencia, Palencia, Spain; Dr. A. Anton from the
Health Complex of Segovia, Segovia, Spain; Dr. L. de Juan-Marcos from the
University Hospital of Salamanca, Salamanca, Spain; and Dr. S. Villaron-Alvarez
from the Health Complex of Avila, Avila, Spain. They all contributed to retrieve
clinical data.
This manuscript is not under consideration by any other journal.
Funding
Novartis-Spain funded this study. The views expressed are those of the authors
and not necessarily the funding body. The researchers are independent of the
funders.
Availability of data and materials
Data generated and analysed during this study are included in this published
article. Supplementary information is available from the corresponding author
on reasonable request.
Authors’ contributions
RMC and MRS contributed to design this study, acquire and analyse data. RMC
critically revised the manuscript. LGB and SDT drafted the manuscript and
revised. IF critically revised the manuscript and performed statistical
analysis. All authors contributed equally in this study. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the ethical committee of the coordinating centre
(IOBA Eye Institute, University of Valladolid) and by the Clinical research Ethics
Committee of East Valladolid Health area, Clinical research Ethics Committee of
Avila Health area, Clinical research Ethics Committee of Leon Health area,
Clinical research Ethics Committee of Palencia Health area, Clinical research
Ethics Committee of Segovia Health area, Clinical research Ethics Committee of
Salamanca Health area. The study was conducted in compliance with the
guidelines in the Declaration of Helsinki. Written informed consent was
obtained from all participants.




Novartis-Spain funds the Novartis Chair and Retina Fellowship (LGB) of the
University of Valladolid.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Instituto de Oftalmobiologia Aplicada (IOBA), Campus Miguel Delibes,
University of Valladolid, P° de Belén n° 17, 47011 Valladolid, Spain. 2Clinic
University Hospital of Valladolid, Valladolid, Spain. 3Health Complex of
Palencia, Palencia, Spain. 4Ciber BBN, Zaragoza, Spain.
Received: 2 January 2017 Accepted: 9 August 2017
References
1. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global
prevalence of age-related macular degeneration and disease burden projection
for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health.
2014;2(2):e106–16.
2. Hanout M, Ferraz D, Ansari M, Maqsood N, Kherani S, Sepah YJ, Rajagopalan N,
Ibrahim M, Do DV, Nguyen QD. Therapies for neovascular age-related macular
degeneration: current approaches and pharmacologic agents in development.
Biomed Res Int. 2013;2013:830837.
3. Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM. Vision-threatening lesions
developing with longer-term follow-up after treatment of neovascular
age-related macular degeneration. Ophthalmology. 2015;122(1):153–61.
4. Kumar N, Mrejen S, Fung AT, Marsiglia M, Loh BK, Spaide RF. Retinal pigment
epithelial cell loss assessed by fundus autofluorescence imaging in neovascular
age-related macular degeneration. Ophthalmology. 2013;120(2):334–41.
5. Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS,
Hagstrom SA, Winter K, et al. Risk of scar in the comparison of age-related
macular degeneration treatments trials. Ophthalmology. 2014;121(3):656–66.
6. Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ,
Fine SL, Blodi B, Klein ML, et al. Risk of geographic atrophy in the comparison
of age-related macular degeneration treatments trials. Ophthalmology.
2014;121(1):150–61.
7. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R,
Fahrbach K, Probst C, Sledge I. The natural history and prognosis of
neovascular age-related macular degeneration: a systematic review of the
literature and meta-analysis. Ophthalmology. 2008;115(1):116–26.
8. Coco RM, Sanabria MR, Castrejon M, Lopez-Galvez MI, Monje-Fernandez L,
Fernandez-Munoz M, Anton A, de Juan-Marcos L, Villaron-Alvarez S,
Fernandez I. Funduscopic results after 4-year follow-up treatment with
ranibizumab for age-related macular degeneration in a region of Spain.
BMC Ophthalmol. 2014;14:138.
9. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen
visual acuity measurements. Retina. 2010;30(7):1046–50.
10. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT,
Klaver CC, Klein BE, Klein R, et al. An international classification and grading
system for age-related maculopathy and age-related macular degeneration.
The international ARM epidemiological study group. Surv Ophthalmol.
1995;39(5):367–74.
11. R Core Team R. A language and environment for statistical computing.
Vienna. URL http://www.R-project.org: R Foundation for Statistical Computing;
2014.
12. Genolini C, Lacombe A, Ecochard R, Subtil F. CopyMean: a new method to
predict monotone missing values in longitudinal studies. Comput Methods
Prog Biomed. 2016;132:29–44.
13. Akaike H. Information theory and an extension of the maximum likelihood
principle. In: 2nd International symposium on information theory; 1973. p.
267–81.
14. McLeod AI XC: bestglm: Best Subset GLM. R package version 0.34. http://CRAN.
R-project.org/package=bestglm. 2014.
15. Fox J, Weisberg S. An {R} companion to applied regression. 2nd ed.
Thousand Oaks: Sage. URL: http://socserv.socsci.mcmaster.ca/jfox/Books/
Companion; 2011.
16. Brier GW. Verification of forecasts expressed in terms of probability. Mon
Weather Rev. 1950;78:1–3.
17. Hosmer D, Lemeshow S. Applied logistic regression. New York: Wiley;
1989. p. 147–56.
18. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M.
pROC: an open-source package for R and S+ to analyze and compare ROC
curves. BMC Bioinformatics. 2011;12:77.
19. de Sisternes L, Simon N, Tibshirani R, Leng T, Rubin DL. Quantitative SD-OCT
imaging biomarkers as indicators of age-related macular degeneration
progression. Invest Ophthalmol Vis Sci. 2014;55(11):7093–103.
20. Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction
model for prevalence and incidence of advanced age-related macular
degeneration based on genetic, demographic, and environmental variables.
Invest Ophthalmol Vis Sci. 2009;50(5):2044–53.
21. Buitendijk GH, Rochtchina E, Myers C, van Duijn CM, Lee KE, Klein BE, Meuer SM,
de Jong PT, Holliday EG, Tan AG, et al. Prediction of age-related macular
degeneration in the general population: the three continent AMD consortium.
Ophthalmology. 2013;120(12):2644–55.
22. Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, Comparison
of Age-related Macular Degeneration Treatments Trials Research G. Growth of
geographic atrophy in the comparison of age-related macular degeneration
treatments trials. Ophthalmology. 2015;122(4):809–16.
23. Schutze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U.
Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of
neovascular age-related macular degeneration. Am J Ophthalmol.
2015;159(6):1100–14. e1101
24. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year
outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON:
a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–9.
25. Kuehlewein L, Dustin L, Sagong M, Hariri A, Mendes TS, Rofagha S, Bhisitkul RB,
Sadda SR. Predictors of macular atrophy detected by Fundus autofluorescence
in patients with Neovascular age-related macular degeneration after long-term
Ranibizumab treatment. Ophthalmic Surg Lasers Imaging Retina.
2016;47(3):224–31.
26. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ,
Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence
tomography-guided, variable dosing regimen with intravitreal ranibizumab
(Lucentis) for neovascular age-related macular degeneration. Am J
Ophthalmol. 2007;143(4):566–83.
27. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL,
Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal
ranibizumab for neovascular age-related macular degeneration: year 2 of
the PrONTO study. Am J Ophthalmol. 2009;148(1):43–58. e41
28. Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA,
Huang J, Martin DF. Association of Baseline Characteristics and Early Vision
Response with 2-year vision outcomes in the comparison of AMD treatments
trials (CATT). Ophthalmology. 2015;122(12):2523–31. e2521
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gonzalez-Buendia et al. BMC Ophthalmology  (2017) 17:147 Page 14 of 14
